Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 14/20 | 0.56 |
| ▸ | ACLY | P53396 | 4/20 | 0.47 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.46 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2120060 | 0.87 | HSD11B1 (0.45) | HSD11B1ACLYSLC40A1 | |
| SCHEMBL2119339 | 0.79 | ACLY (0.48) | HSD11B1ACLY | |
| SCHEMBL2119379 | 0.79 | SLC40A1 (0.46) | HSD11B1ACLYSLC40A1 | |
| SCHEMBL2118652 | 0.77 | TRIM24 (0.48) | HSD11B1SLC40A1 | |
| SCHEMBL2119342 | 0.77 | GHSR (0.48) | ACLYSLC40A1 | |
| SCHEMBL2119214 | 0.77 | SLC40A1 (0.46) | HSD11B1ACLYSLC40A1 | |
| SCHEMBL2117134 | 0.76 | SLC40A1 (0.46) | SLC40A1 | |
| SCHEMBL2119029 | 0.76 | ACLY (0.49) | HSD11B1ACLY | |
| SCHEMBL2119213 | 0.76 | ACLY (0.49) | HSD11B1ACLY | |
| SCHEMBL2120200 | 0.75 | ACLY (0.48) | HSD11B1ACLYPTGES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | ELARA PHARMACEUTICALS GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| EP-2382190-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE AS-INHIBITORS | European Molecular Biology Laboratory (EMBL) (DE) | 2011-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | HIF1A, HIF1AN, EGLN3 | HSD11B1 3376/4885ACLY 1578/4885SLC40A1 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.